Sanz-Álvarez, M.; Cristóbal, I.; Luque, M.; Santos, A.; Zazo, S.; Madoz-Gúrpide, J.; Caramés, C.; Chiang, C.-M.; García-Foncillas, J.; Eroles, P.;
et al. Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. Cancers 2021, 13, 1246.
https://doi.org/10.3390/cancers13061246
AMA Style
Sanz-Álvarez M, Cristóbal I, Luque M, Santos A, Zazo S, Madoz-Gúrpide J, Caramés C, Chiang C-M, García-Foncillas J, Eroles P,
et al. Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. Cancers. 2021; 13(6):1246.
https://doi.org/10.3390/cancers13061246
Chicago/Turabian Style
Sanz-Álvarez, Marta, Ion Cristóbal, Melani Luque, Andrea Santos, Sandra Zazo, Juan Madoz-Gúrpide, Cristina Caramés, Cheng-Ming Chiang, Jesús García-Foncillas, Pilar Eroles,
and et al. 2021. "Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients" Cancers 13, no. 6: 1246.
https://doi.org/10.3390/cancers13061246
APA Style
Sanz-Álvarez, M., Cristóbal, I., Luque, M., Santos, A., Zazo, S., Madoz-Gúrpide, J., Caramés, C., Chiang, C.-M., García-Foncillas, J., Eroles, P., Albanell, J., & Rojo, F.
(2021). Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. Cancers, 13(6), 1246.
https://doi.org/10.3390/cancers13061246